Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terry Vance Insider Profile
4 Followers
Terry Vance, Director at Enanta Pharmaceuticals, holds 5.80K shares in Enanta Pharmaceuticals (Ticker: ENTA). Most recently, Terry Vance Sold $15,295 shares of Enanta Pharmaceuticals on Dec 15, 2023 for an estimated value of 139.49K.
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-9.30%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Terry Vance holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Feb 17, 2016 - Feb 17, 2017
Return:-0.20%
The most profitable trade made by Terry Vance
Terry Vance's Trading History
List of latest transactions for each holding click on a transaction to see Terry Vance's performance on stock
You May Also Like
Terry Vance insider profile FAQ
What is the percentage of profitable transactions made by Terry Vance?
The percentage of profitable transactions made by Terry Vance is 0%.
What is the average return per transaction made by Terry Vance?
The average return per transaction made by Terry Vance is -9.30%.
What stocks does Terry Vance hold?
Terry Vance holds: ENTA stocks.
What was Terry Vance’s latest transaction?
Terry Vance latest transaction was an Informative Sell of $139.49K.
What was Terry Vance's most profitable transaction?
Terry Vance’s most profitable transaction was an Informative Buy of ENTA stock on February 17, 2016. The return on the trade was -0.20%.
What is Terry Vance's role in Enanta Pharmaceuticals?
Terry Vance's role in Enanta Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.